What are the recommended dosing regimens for Ozempic (semaglutide)?

Ozempic (Semaglutide) Dosing Regimens

For type 2 diabetes, initiate Ozempic at 0.25 mg subcutaneously once weekly for 4 weeks, then escalate to 0.5 mg weekly; if additional glycemic control is needed after at least 4 weeks on 0.5 mg, increase to 1 mg weekly (maximum approved dose for diabetes). 1

Standard Titration for Type 2 Diabetes

• Start with 0.25 mg once weekly for the first 4 weeks – this dose is not therapeutic but serves solely to minimize gastrointestinal adverse events during initiation 2, 1
• Escalate to 0.5 mg once weekly after 4 weeks – this represents the first therapeutic maintenance dose 2, 1
• Consider increasing to 1 mg once weekly if glycemic targets remain unmet after at least 4 weeks on the 0.5 mg dose 2, 1
• The 1 mg weekly dose is the maximum FDA-approved dose for type 2 diabetes management 1

Extended Titration for Obesity Management

For weight management in patients with BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidities), use a stepwise escalation to reach the 2.4 mg weekly maintenance dose: 2

• Weeks 1-4: 0.25 mg weekly 2
• Weeks 5-8: 0.5 mg weekly 2
• Weeks 9-12: 1.0 mg weekly 2
• Weeks 13-16: 1.7 mg weekly 2
• Week 17 onward: 2.4 mg weekly (maintenance dose for obesity) 2

This obesity-focused regimen is supported by the STEP trial program, which demonstrated mean weight loss of 14.9-16.0% at 68 weeks 3

Administration Logistics

• Inject subcutaneously once weekly on the same day each week, at any time of day, with or without meals 2, 1
• Rotate injection sites (abdomen, thigh, or upper arm) to reduce local reactions 1
• If a dose is missed: administer within 5 days of the scheduled dose, then resume the regular weekly schedule; if >5 days have passed, skip the missed dose entirely and give the next dose on the regularly scheduled day 1
• If changing the weekly injection day: ensure at least 2 days (>48 hours) elapse between doses 1

Flexible Titration for Gastrointestinal Intolerance

A slower, individualized titration schedule significantly improves adherence and reduces adverse events without compromising efficacy. 4

• Recent randomized controlled trial data demonstrate that flexible titration (starting at 0.0675 mg with weekly increases of 0.0675 mg, with delays for GI symptoms) reduced treatment discontinuation due to GI adverse events from 19% to 2% compared with label-recommended titration 4
• Patients in the flexible arm experienced fewer days of nausea (2.88 vs 6.3 days; p=0.017) and less asthenia (9.8% vs 24.5%; p=0.047) 4
• If patients experience significant nausea, vomiting, or diarrhea, delay dose escalation until tolerance improves – this approach does not compromise HbA1c or BMI outcomes 4
• If ≥3 consecutive doses are missed, restart the entire titration schedule from the beginning 2

Renal and Hepatic Dosing

• No dose adjustment required for any degree of renal impairment, including eGFR 15-29 mL/min/1.73 m², eGFR <15 mL/min/1.73 m², or end-stage renal disease 5, 2
• This distinguishes semaglutide from other GLP-1 receptor agonists that require dose reduction or are contraindicated in advanced kidney disease 5, 2
• No dose adjustment required for hepatic impairment 2

Concomitant Medication Adjustments

When combining semaglutide with insulin or sulfonylureas, proactively reduce doses of these agents to prevent hypoglycemia. 2

• Semaglutide monotherapy carries minimal intrinsic hypoglycemia risk due to its glucose-dependent mechanism 2
• In the SUSTAIN 4 trial, severe or blood glucose-confirmed hypoglycemia occurred in only 4-6% of semaglutide-treated patients versus 11% with insulin glargine (p=0.0021-0.0202) 6
• Do not co-administer with other GLP-1 receptor agonists or DPP-4 inhibitors 2
• Semaglutide delays gastric emptying and may alter absorption of oral medications requiring rapid onset 2

Common Adverse Events and Management

• Nausea occurs in approximately 40% of patients, vomiting in 16%, and diarrhea at comparable frequency – these are dose-dependent and typically transient 2
• Most gastrointestinal events are mild-to-moderate and improve with gradual titration 7
• The 4-week dose escalation regimen selected for phase 3 trials was specifically designed to mitigate these effects 7

Absolute Contraindications

Do not prescribe Ozempic in patients with: 2

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia type 2 (MEN 2)
• Known serious hypersensitivity to semaglutide

Storage and Handling

• Store unused pens refrigerated at 36-46°F (2-8°C) until first use 1
• Once in use, store at room temperature 59-86°F (15-30°C) or continue refrigeration for up to 56 days 1
• Discard pens 56 days after first use, even if medication remains 1
• Do not freeze; discard if frozen 1

Higher-Dose Option for Inadequate Response

• A 2.0 mg weekly dose (not yet FDA-approved for routine use in the US) demonstrated superior HbA1c reduction (-0.23 percentage points; p=0.0003) and additional weight loss (-0.93 kg; p=0.015) compared with 1.0 mg in the SUSTAIN FORTE trial 8
• This higher dose provides a potential intensification option for patients requiring additional glycemic control beyond the standard 1 mg dose 8